Literature DB >> 25683513

Anti-HLA sensitization in extensively burned patients: extent, associated factors, and reduction in potential access to vascularized composite allotransplantation.

Patrick Duhamel1, Caroline Suberbielle, Philippe Grimbert, Thomas Leclerc, Christian Jacquelinet, Benoit Audry, Laurent Bargues, Dominique Charron, Eric Bey, Laurent Lantieri, Mikael Hivelin.   

Abstract

Extensively burned patients receive iterative blood transfusions and skin allografts that often lead to HLA sensitization, and potentially impede access to vascularized composite allotransplantation (VCA). In this retrospective, single-center study, anti-HLA sensitization was measured by single-antigen-flow bead analysis in patients with deep, second- and third-degree burns over ≥40% total body surface area (TBSA). Association of HLA sensitization with blood transfusions, skin allografts, and pregnancies was analyzed by bivariate analysis. The eligibility for transplantation was assessed using calculated panel reactive antibodies (cPRA). Twenty-nine patients aged 32 ± 14 years, including 11 women, presented with a mean burned TBSA of 54 ± 11%. Fifteen patients received skin allografts, comprising those who received cryopreserved (n = 3) or glycerol-preserved (n = 7) allografts, or both (n = 5). An average 36 ± 13 packed red blood cell (PRBC) units were transfused per patient. In sera samples collected 38 ± 13 months after the burns, all patients except one presented with anti-HLA antibodies, of which 13 patients (45%) had complement-fixing antibodies. Eighteen patients (62%) were considered highly sensitized (cPRA≥85%). Cryopreserved, but not glycerol-preserved skin allografts, history of pregnancy, and number of PRBC units were associated with HLA sensitization. Extensively burned patients may become highly HLA sensitized during acute care and hence not qualify for VCA. Alternatives to skin allografts might help preserve their later access to VCA.
© 2015 Steunstichting ESOT.

Entities:  

Keywords:  anti-HLA antibodies; composite tissue allograft; donor-recipient matching; sensitization; simulated allocation modelling; skin allograft

Mesh:

Substances:

Year:  2015        PMID: 25683513     DOI: 10.1111/tri.12540

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  8 in total

Review 1.  Scar management in burn injuries using drug delivery and molecular signaling: Current treatments and future directions.

Authors:  Saeid Amini-Nik; Yusef Yousuf; Marc G Jeschke
Journal:  Adv Drug Deliv Rev       Date:  2017-07-27       Impact factor: 15.470

2.  Longitudinal immunological characterization of the first presensitized recipient of a face transplant.

Authors:  Thet Su Win; Naoka Murakami; Thiago J Borges; Anil Chandraker; George Murphy; Christine Lian; Victor Barrera; Shannan Ho Sui; David Schoenfeld; Jessica Teague; Ericka Bueno; Stefan G Tullius; Bohdan Pomahac; Rachael A Clark; Leonardo V Riella
Journal:  JCI Insight       Date:  2017-07-06

Review 3.  Hypertrophic scarring: the greatest unmet challenge after burn injury.

Authors:  Celeste C Finnerty; Marc G Jeschke; Ludwik K Branski; Juan P Barret; Peter Dziewulski; David N Herndon
Journal:  Lancet       Date:  2016-10-01       Impact factor: 79.321

Review 4.  Accommodation and related conditions in vascularized composite allografts.

Authors:  Jeffrey L Platt; Christina L Kaufman; Mayara Garcia de Mattos Barbosa; Marilia Cascalho
Journal:  Curr Opin Organ Transplant       Date:  2017-10       Impact factor: 2.640

Review 5.  Advances in machine perfusion, organ preservation, and cryobiology: potential impact on vascularized composite allotransplantation.

Authors:  Laura C Burlage; Shannon N Tessier; Joanna W Etra; Korkut Uygun; Gerald Brandacher
Journal:  Curr Opin Organ Transplant       Date:  2018-10       Impact factor: 2.640

Review 6.  Vascularized composite allotransplantation: current standards and novel approaches to prevent acute rejection and chronic allograft deterioration.

Authors:  Maximilian Kueckelhaus; Sebastian Fischer; Midas Seyda; Ericka M Bueno; Mario A Aycart; Muayyad Alhefzi; Abdallah ElKhal; Bohdan Pomahac; Stefan G Tullius
Journal:  Transpl Int       Date:  2015-09-14       Impact factor: 3.782

7.  Absence of Rejection in a Facial Allograft Recipient with a Positive Flow Crossmatch 24 Months after Induction with Rabbit Anti-Thymocyte Globulin and Anti-CD20 Monoclonal Antibody.

Authors:  Bruce E Gelb; J Rodrigo Diaz-Siso; Natalie M Plana; Adam Jacoby; William J Rifkin; Kimberly S Khouri; Daniel J Ceradini; Eduardo D Rodriguez
Journal:  Case Rep Transplant       Date:  2018-05-20

Review 8.  Face Transplant: Indications, Outcomes, and Ethical Issues-Where Do We Stand?

Authors:  Simone La Padula; Rosita Pensato; Chiara Pizza; Edoardo Coiante; Giovanni Roccaro; Benedetto Longo; Francesco D'Andrea; Francesco Saverio Wirz; Barbara Hersant; Jean Paul Meningaud
Journal:  J Clin Med       Date:  2022-09-28       Impact factor: 4.964

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.